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Progress in preventing atherosclerotic coronary artery disease (CAD) has been stalled by the epidemic of
type 2 diabetes. Further advances in this area demand a thorough understanding of how two major features
of type 2 diabetes, insulin resistance and hyperglycemia, impact atherosclerosis. Insulin resistance is asso-
ciated with systemic CAD risk factors, but increasing evidence suggests that defective insulin signaling in
atherosclerotic lesional cells also plays an important role. The role of hyperglycemia in CAD associated
with type 2 diabetes is less clear. Understanding the mechanisms whereby type 2 diabetes exacerbates
CAD offers hope for new therapeutic strategies to prevent and treat atherosclerotic vascular disease.Introduction
Atherothrombotic cardiovascular disease is the leading cause of
deathworldwide despite significant progress in themanagement
of critical risk factors (Callow, 2006). Amajor reason for this trend
is the ongoing epidemic of obesity-induced insulin resistance
and type 2 diabetes (Behn and Ur, 2006). An important goal in
preventive medicine, therefore, is to reverse this trend. On the
one hand, public health measures that address overnutrition
and lack of physical exercise are key. However, achieving
success in life-style changes has been extremely challenging,
and so complementary approaches that identify potential thera-
peutic targets relevant to atherosclerosis per se in diabetics are
needed. This approach requires a thorough understanding of
how insulin resistance and type 2 diabetes promote atheroscle-
rosis. There are fundamental gaps in this area. Most notably, we
need to more fully understand the relative importance of (a)
insulin resistance versus hyperglycemia and the concept that
‘‘insulin resistance’’ can mean either defective insulin receptor
signaling or, ironically, overstimulation of insulin receptor path-
ways caused by hyperinsulinemia (Brown and Goldstein,
2008); and (b) systemic risk factors induced by these syndromes
versus direct processes acting at the level of the arterial wall.
Another important issue is related to the point that the patho-
physiological processes involved in the initiation and progres-
sion of early lesions are quite different from those that cause
the formation of clinically dangerous plaques (Lusis, 2000; Ta-
bas, 2010a), and distinguishing the effects of insulin resistance
and hyperglycemia on these processes is critically important.
Early-to-mid-stage atherogenesis involves the subendothelial
retention of apolipoprotein B (apoB)-containing lipoproteins;
activation of endothelial cells; recruitment of monocytes and
other inflammatory cells; cholesterol loading of lesional cells;
and migration of smooth muscle cells to the intima. In contrast,
advanced plaque progression is influenced primarily by
processes that promote plaque necrosis and thinning of a collag-
enous ‘‘scar’’ overlying the lesion called the fibrous cap. The
focused objective here is to review current knowledge on how
insulin resistance and hyperglycemia may promote atherogen-esis and advanced plaque progression by affecting the biology
of atherosclerotic lesional cells, emphasizing studies that are
mechanistically sound and include evidence of causation in vivo.
It should be noted that insulin resistance and hyperglycemia are
likely to have additive or synergistic proatherogenic effects in the
setting of type 2 diabetes. For example, glucotoxicity may
contribute to insulin resistance, and treatment of hyperglycemia
in type 2 diabetes improves insulin resistance in some tissues
(Henry, 1996). For ease of presentation, however, the effects
on insulin resistance and hyperglycemia on atherosclerosis are
discussed in separate sections in this review.
Insulin Resistance and Atherosclerosis
There is ample clinical evidence that insulin resistance increases
the risk for coronary artery disease (CAD) even in the absence of
hyperglycemia (DeFronzo, 2010). Insulin resistance syndromes
can promote both atherogenesis and advanced plaque progres-
sion, and the mechanisms likely involve both systemic factors
that promote these processes, particularly dyslipidemia but
also hypertension and a proinflammatory state, as well as the
effect of perturbed insulin signaling at the level of the intimal
cells that participate in atherosclerosis, including endothelial
cells, vascular smooth muscle cells, and macrophages (Figures
1 and 2). All three cell types have insulin receptors and insulin
receptor-mediated signaling pathways that are downregulated
markedly, though not completely, in the setting of hyperinsuline-
mia (Rask-Madsen et al., 2010). To review, insulin receptor (IR)
activation by insulin leads to the recruitment of IR substrate-1
and -2 (IRS) and phosphoinositide 3 (PI3)-kinase to the
cytoplasmic tail of the IR (Kido et al., 2001) (Figure 1, inset).
PI3-kinase forms phosphatidylinositol 3,4,5 trisphosphate
[PtdIns(3,4,5)P3] in the plasma membrane, which in turn recruits
3-phosphoinositide-dependent protein kinase 1 (PDK1). PDK1
activates various isoforms of protein kinase B (PKB)/Akt, which
mediate many actions of the IR, including phosphorylation/
nuclear exclusion of FoxO proteins, which are transcription
factors for many metabolic genes; phosphorylation/inactivation
of glycogen synthase kinase-3 (GSK3), which promotesCell Metabolism 14, November 2, 2011 ª2011 Elsevier Inc. 575
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Insulin Resistance in ECs, VSMCs, and
Macrophages Promotes Atherogenesis
In early/mid-stage atherosclerotic lesions, insulin resis-
tance is associated with a decrease in eNOS activation
andNO production and increase in VCAM-1 expression by
arterial ECs. Both of these perturbations may be due to
downregulation of the insulin receptor-Akt1 pathway in
ECs. The net effect is endothelial dysfunction and activa-
tion, leading to defective vasodilation and increased entry
of inflammatory cells into the plaque. Inset, summary
scheme of canonical insulin receptor signaling pathway;
see text for details. Lps, lipoproteins.
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mTOR, which promotes protein translation. These and other IR
pathways also activate mitogen-activated protein kinases,
hepatic lipid synthesis pathways, and glucose transporter
translocation to the cell surface. As alluded to above, ‘‘insulin
resistance’’ can refer to downregulated IR signaling or hyperin-
sulinemia-mediated excessive IR signaling. Most of the experi-
mental work in atherosclerosis has focused on the suppression
of IR signaling and has used proof-of-concept models in which
IRs, or their adaptors, in these cell types have been genetically
eliminated.
Endothelial Cells
In a nonatherosclerotic mouse model in which the endothelial
cell (EC) IR was targeted using the Cre-loxP method, ECs and
aorta showed reduced levels of endothelial nitric oxide synthe-
tase (eNOS) and endothelin-1 mRNA (Vicent et al., 2003). To
address atherosclerosis, the mice were crossed onto the
Apoe/ background (‘‘EIRAKO’’) and maintained on a chow
diet for 24 or 52 weeks. Several measures of atherosclerosis
were increased in the EIRAKO versus control mice despite no
difference in plasma lipids, glucose, insulin, or blood pressure
(Rask-Madsen et al., 2010).
Mechanistic studies focused on two key atherogenic proper-
ties of ECs, suppression of eNOS activity and adhesion of leuko-
cytes. In wild-type ECs and aorta, insulin was able to induce
phosphorylation of eNOS on Ser1177, which is a measure of
the enzyme’s activation state, and suppress VCAM-1, which
is a key endothelial-leukocyte adhesion molecule in atherogen-
esis. Both of these effects of insulin, which are predicted to be
antiatherogenic, were decreased in EIRAKO aorta and in lung
and aortic ECs isolated from the mice. As predicted from these
data, EIRAKO aorta had decreased acetylcholine-induced vaso-576 Cell Metabolism 14, November 2, 2011 ª2011 Elsevier Inc.dilation, but no resistance to direct application
of NO, and VCAM-1-dependent leukocyte roll-
ing and adhesion were increased in the KO
mice. Thus, normal IR signaling in vascular
endothelium appears to induce a number of
processes that are athero-protective. If so,
downregulation of endothelial IRs may explain
one mechanism of atherogenesis in the setting
of insulin resistance. However, whether endo-
thelial insulin resistance affects the progression
to necrotic plaques, which are the clinically rele-
vant lesions in humans, remains to be explored.
A critical issue in insulin resistance is the iden-
tity of the branch(es) of IR pathways that aredownregulated in the setting of hyperinsulinemia. In one study,
insulin-induced PI3K and Akt phosphorylation was suppressed
in the aorta and microvessels of obese rats, but the ERK-1/2
pathway was not suppressed (Jiang et al., 1999). However,
another study investigating endothelial dysfunction and
decreased eNOS Ser1177 phosphorylation in obese, insulin-
resistantmice impugned high levels of free fatty acids, not defec-
tive IR-Akt1 signaling (Symons et al., 2009). Moreover, another
study showed that insulin can activate eNOS in ECs through
induction of fatty acid synthase,which promotes eNOSpalmitoy-
lation and translocation to the plasma membrane (Wei et al.,
2011). These complexities highlight the importance of a study
that investigated the effect of genetically targeting Akt1 in
Apoe/ mice fed the high-fat Western-type diet for 14 weeks,
which is a model of atherosclerosis and insulin resistance (Fer-
na´ndez-Hernando et al., 2007). Akt1/Apoe/ mice showed
an increase in aortic atherosclerosis compared with Apoe/
mice; very large coronary arterial lesions, which are rarely seen
in nonaged mouse models of atherosclerosis; increased
lesional inflammatory cytokines and decreased p-S1176-
eNOS. ECs isolated from the double KOmice showed decreased
proliferation and viability, whichmay compromise vascular repair
in response to injury, and bone marrow transplant experiments
showed that the effect of Akt1 deficiency on lesion area was
due to non-myeloid-derived cells, consistent with a role for
ECs. Thus, in fat-fed Apoe/mice, downregulation of the endo-
thelial Akt1 phosphorylation pathway plays a role in the proa-
therogenic effects of insulin resistance. However, the differences
in the diet, timing, and endpoints between the EIRAKO and
Akt1/Apoe/ studies, and the fact that the latter study was
not endothelial-specific, makes it difficult to draw more precise
conclusions.
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Figure 2. Possible Mechanisms through which
Insulin Resistance in ECs, VSMCs, and
Macrophages Promotes Advanced Plaque
Progression
In advanced plaques, insulin resistance may promote
apoptosis of all threemajor cell types. Death of VSMCs can
lead to fibrous cap thinning, while death of macrophages,
coupled with defective phagocytic clearance of the cells
(efferocytosis), promotes plaque necrosis. Both fibrous
cap thinning and plaque necrosis can precipitate plaque
rupture and acute thrombotic vascular occlusion. Not
shown in this scheme is the possibility that elevated
saturated fatty acids associated with obesity and insulin
resistance causes defective efferocytosis of apoptotic
macrophages.
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Vascular smooth muscle cells (VSMCs) express heterodimers of
IRs and insulin-like growth factor-1 receptors (IGF1Rs), and
in vitro data suggest that the effects of insulin in VSMCs are
mediated mostly through IGF1R, despite the fact that insulin
has a higher affinity for IRs than for IGF1R (Johansson and
Arnqvist, 2006). Thus, there is much uncertainty as to the role
of VSMCs in mediating the atherogenic effects of insulin resis-
tance. One hypothesis is that hyperinsulinemia, by selectively
downregulating IRs, promotes the formation of ‘‘proathero-
genic’’ IGF1R homodimers. As a proof-of-concept model,
IR-deficient VSMCs were incubated with insulin, and this led
to decreased activation of Akt, increased activation of ERK-1/2,
and increased proliferation and migration, presumably through
IGF1R signaling (Lightell et al., 2011). Conversely, IGF1R
silencing by siRNA in cultured VSMCs to ‘‘force’’ signaling
through IRs enhanced insulin-induced Akt activation (Engberd-
ing et al., 2009). These data raise the possibility that an imbal-
ance of IGF1R over IR signaling in insulin resistant states may
favor pathways that promote atherosclerosis. The importance
of Akt downregulation was suggested by a study showing
that Akt1/ VSMCs had decreased proliferation and migration,
as well as increased susceptibility to apoptosis (Ferna´ndez-
Hernando et al., 2009). Increased VSMC proliferation and
migration would be expected to promote early/mid-stage
atherosclerosis by converting a fatty streak to a more irrevers-
ible VSMC-rich plaque. Ironically, in advanced plaques, intimal
VSMCs may lessen the risk of plaque rupture through fibrous
cap collagen synthesis, but this beneficial effect may be offset
in the setting of insulin resistance by enhanced SMC apoptosis,
perhaps via disruption of Akt cell-survival signaling. Intact
IR signaling was also shown to suppress TNF-a-induced
NF-kB activation in VSMCs with silenced IGF1R (Engberding
et al., 2009), suggesting another mechanism whereby loss of
intact IR signaling in the setting of hyperinsulinemia may be
atherogenic.Cell MetabolisOther data, however, question the idea that
an increase in IGF1R versus IR signaling in
VSMCs promotes atherosclerosis in the setting
of insulin resistance. First, gene expression
studies have shown that downstream signaling
from IGF1R and IR are very similar (Boucher
et al., 2010). Second, a number studies have
suggested that IGF1R signaling protectsVSMCs from apoptosis (Allard et al., 2008), and when IGF1
was overexpressed in VSMCs in Apoe/ mice, lesion size was
not altered and plaque stability was actually increased, not
decreased (Shai et al., 2010). Moreover, there is a possibility
that obesity and insulin resistance may be associated with
a decrease in signaling originating from both receptors. For
example, obesity is associated with higher levels of angiotensin
II (Olivares-Reyes et al., 2009), and angiotensin II promotes the
degradation of the common IR/IGF1R adaptor IRS-1 in VSMCs
(Taniyama et al., 2005). Furthermore, other potential atherogenic
effects in VSMCs associated with insulin resistance have not yet
been linked to disturbances in IR or IGF1R signaling. As an
example, VSMCs from prediabetic obese rats demonstrate
increased NADPH oxidase-induced oxidative stress through
a pathway involving transforming growth factor-b (Tong et al.,
2010). These complexities and uncertainties highlight the critical
need for studies that address whether insulin resistance alters
the biology of lesional VSMCs in vivo and, if so, whether these
alterations affect atherogenesis and/or advanced plaque
progression.
Macrophages
Monocyte-derived macrophages play critical roles in all stages
of atherosclerosis (Moore and Tabas, 2011). In early lesions,
monocytes are recruited to the intima by activated endothelium
overlying areas of apoB-lipoprotein retention and then, after
differentiation to macrophages in the intima, ingest these re-
tained lipoproteins to become cholesterol-loaded foam cells.
Intimal macrophages participate in a number of proatherogenic
processes, including inflammation, secretion of proteases and
procoagulant/thrombotic factors, and formation of the necrotic
core of clinically dangerous lesions (below).
Macrophage IRs are markedly downregulated in the settings
of obesity and hyperinsulinemia, and there is evidence that
defective IR signaling promotes atherosclerosis (Tabas et al.,
2010). In one study, the Cre-loxP strategy was used to target
IRs in lysozyme M-expressing myeloid cells (Baumgartl et al.,m 14, November 2, 2011 ª2011 Elsevier Inc. 577
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phils, and, to a lesser degree, monocytes. Importantly, the
IR-floxed mice were on a mixed genetic background, which
can have profound effects on atherosclerosis, and the diet
included a high concentration of cholesterol and cholate, which
promotes inflammation (Vergnes et al., 2003). When placed on
the Apoe/ background and fed that diet for 4 months, the
myeloid IR deficient mice displayed a 50% reduction in en
face aortic lesion area compared with Apoe/ mice despite
no effect on plasma lipoproteins, glucose, or insulin. To sub-
stantiate these findings using a different strategy, the investiga-
tors conducted an Apoe/ bone marrow transplant experiment
using donor marrow from control Apoe/mice versus Apoe/
mice lacking the macrophage IR adaptor IRS-2. Both aortic root
en face and cross-sectional area were reduced 25%–30% in
the Irs2/Apoe/mice. Thus, in the setting of a mixed genetic
background and a ‘‘proinflammatory’’ diet, macrophage IR
signaling seems to modestly promote atherogenesis. With re-
gard to inflammation, in vitro studies showed that the IR-defi-
cient macrophages had blunted IL-6 and IL-1b responses to
LPS. The molecular mechanism of this anti-inflammatory effect,
and whether it can explain the lesional results in vivo, remains to
be determined, although the mechanism is likely related to the
finding that nuclear FoxO1, a hallmark of insulin resistance,
suppresses NF-kB signaling (Senokuchi et al., 2008). As a final
note, the IRS-2 bone marrow transplant experiment was accom-
panied by a holo-Irs2/ experiment to assess the effect of
systemic hyperinsulinemia on atherogenesis. In this case, the
lesions were slightly larger in the KO group, suggesting that the
proatherogenic effects of systemic insulin resistance trumped
the putative antiatherogenic effects of defective macrophage
IR signaling.
Another study used a different model, namely, transplantation
of IR KO bonemarrow into C57BL6 Ldlr/mice fed theWestern
diet, which has a lower cholesterol content without cholate (Han
et al., 2006). Most importantly, the primary objective of this study
was to address an entirely different question, namely, the effect
of myeloid IR deficiency on advanced lesional macrophage
apoptosis and plaque necrosis. Recall that most atherosclerotic
lesions in humans do not cause acute coronary artery disease,
because they undergo outward remodeling of the arterial wall,
which preserves lumen patency, and do not undergo plaque
rupture or erosion and thus do not trigger acute lumenal throm-
bosis (Virmani et al., 2002). The small percentage of lesions that
do cause acute vascular disease are distinguished by the pres-
ence of large areas of necrosis and thin fibrous caps, which
promote plaque disruption, acute lumenal thrombosis, and
tissue infarction (Tabas, 2011). This concept is particularly
important for the topic of this review, because advanced athero-
sclerotic lesions in diabetic subjects are characterized by large
necrotic cores when compared with similarly sized lesions
from nondiabetic individuals (Tabas et al., 2010).
The mechanistic basis of the study by Han et al. was a series
of in vitro investigations exploring how defective IR signaling in
macrophages might promote the type of apoptotic processes
that are thought to occur in advanced lesions (Han et al.,
2006). By way of background, mechanistic and in vivo data in
mice and humans support a role for prolonged endoplasmic
reticulum (ER) stress in advanced lesional macrophage578 Cell Metabolism 14, November 2, 2011 ª2011 Elsevier Inc.apoptosis and plaque necrosis, primarily through the action of
the ER stress effector C/EBP-homologous protein (CHOP) (Ta-
bas, 2010b). Macrophages from obese, insulin-resistant mice
or mice lacking IRs demonstrate enhanced ER-stress-induced
apoptosis, which is mediated through at least three mecha-
nisms: (a) upregulation of scavenger receptors (Liang et al.,
2004), which are activated in atherosclerosis and signal to
enhance ER stress-induced macrophage apoptosis (Tabas,
2010b); (b) suppression of Akt andNF-kB cell-survival pathways,
the latter of which is mediated by nuclear FoxO1 (Senokuchi
et al., 2008); and (c) downregulation of the ER calcium pump
SERCA, which promotes the accumulation of cytoplasmic
calcium (C. P. Liang, S. Han, G. Li, T. Senokuchi, I.T., and A.R.
Tall, unpublished data). This latter mechanism is likely relevant
to the recent finding that CHOP promotes macrophage
apoptosis by stimulating the release of calcium from the ER,
which subsequently activates an apoptosis execution program
coordinated by calcium/calmodulin-dependent protein kinase
II (CaMKII) (Tabas and Ron, 2011).
With this background, Western diet-fed Insr/ / Ldlr/
chimeric mice showed a significant increase in advanced le-
sional macrophage apoptosis and plaque necrosis compared
with WT/ Ldlr/ mice (Han et al., 2006). Further mechanistic
studies will be needed to link the aforementioned mechanisms
to this in vivo result, although a subsequent study showed that
the lesions of Akt1/Apoe/mice had more apoptotic macro-
phages than those of Apoe/mice (Ferna´ndez-Hernando et al.,
2007). Finally, in contrast to the result in the cholate-diet study
described in the previous section, cross-sectional aortic root
lesion area was similar between Western diet-fed Apoe/
mice with normal or absent myeloid insulin receptors (Han
et al., 2006). This apparent inconsistency may reflect differences
in genetic background and/or diet. For example, it is possible
that the NF-kB-suppressive effect of macrophage insulin resis-
tance (Senokuchi et al., 2008) may play a dominant, athero-
protective role when mice are placed on the proinflammatory
high cholesterol/cholate diet.
Another characteristic of insulin-resistant states is elevated
levels of free fatty acids (Boden and Shulman, 2002). It is gener-
ally believed that saturated fatty acids (SFAs) are the most detri-
mental, and SFAs can trigger ER stress-induced apoptosis in
macrophages, perhaps by decreasing the fluidity of the ER
membrane (Borradaile et al., 2006). Macrophage ER stress and
apoptosis induced by SFAs in vitro and in aortic root lesions of
fat-fed Apoe/ mice appear to require an intracellular ‘‘lipid
chaperone’’ called macrophage fatty acid-binding protein-4,
also known as aP2 (Erbay et al., 2009). The requirement for
aP2may be related to its ability to prevent stearoyl-CoA desatur-
ase-mediated conversion of SFAs to unsaturated fatty acids,
which are much less lipotoxic than SFAs. SFAs can also amplify
the apoptotic response in macrophages exposed to other ER
stressors in vitro and in vivo through a CD36-mediated signaling
mechanism that promotes oxidative stress (Seimon et al., 2010).
Finally, macrophages from obese mice, including those in
advanced atherosclerotic lesions of ob/obLdlr/ mice, have
a decreased ability to ingest apoptotic cells (efferocytosis) (Li
et al., 2009). Defective efferocytosis leads to secondary cellular
necrosis and inflammation and is thought to be a critical patho-
logical process leading to plaque necrosis (Tabas, 2010a). The
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phagocytosis by decreasing the fluidity of the plasmamembrane
(Li et al., 2009). Although this finding will require further investiga-
tion, the combined proapoptotic effect of macrophage insulin
resistance and the antiefferocytic effect of SFAs may create
a ‘‘perfect storm’’ for plaque necrosis.
Hyperglycemia and Atherosclerosis
Data from human and animal studies supporting a direct proa-
therogenic role of hyperglycemia in vascular cells are not as
strong as those for insulin resistance, but there is suggestive
evidence that high glucose is atherogenic, particularly at the
level of the arterial endothelium. In this section, we will summa-
rize the evidence that hyperglycemia can promote atheroscle-
rosis and discuss selected mechanisms that are supported by
mechanistic and in vivo causation studies.
Evidence from Human Studies and Animal Models
Several clinical studies demonstrate a correlation between
suboptimal glycemic control and cardiovascular events and
suggest a CAD benefit of glucose lowering in patients with
type 2 diabetes (Brown et al., 2010; Mazzone, 2010). The most
compelling evidence comes from long-term follow-up studies
in which intensive glucose lowering was initiated soon after dia-
betes diagnosis or before the onset of cardiovascular events
(Brown et al., 2010). For example, the DCCT-EDIC study demon-
strated an impressive 57% reduction in the risk of nonfatal
myocardial infarction (MI), stroke, or death from cardiovascular
disease in the intensive glucose-lowering group of subjects
with type 1 diabetes compared with the conventionally treated
group (Nathan et al., 2005). Similar beneficial effects of blood
glucose lowering have been reported in newly diagnosed
subjects with type 2 diabetes (Holman et al., 2008). At the level
of the vascular wall, human postmortem studies show that
lesions from patients with diabetes have a higher macrophage
content than lesions from subjects without diabetes, in a manner
that correlates with glycated hemoglobin levels rather than lipid
levels (Burke et al., 2004).
However, the relationship between hyperglycemia and CAD is
still unclear (Brown et al., 2010; Mazzone, 2010). For example,
a recent large study demonstrated that whereas intensive blood
glucose control for 3.7 years in patients with advanced type 2
diabetes and a pre-existing high risk of cardiovascular disease
reduced 5-year nonfatal MI, it increased 5-year mortality, as
compared with patients receiving standard therapy (Gerstein
et al., 2011). The increased mortality in the intensive therapy
group might have been due to the larger number of glucose-
lowering drugs used to achieve glycated hemoglobin levels of
<6% or to other unidentified factors.
There are a number of issues that might explain, at least
in part, the confusion in this area. First, type 2 diabetes is asso-
ciated with several cardiovascular risk factors as discussed
above, and hyperglycemia may provide a relatively minor contri-
bution to overall CAD risk. Second, elevated glycated hemo-
globin A1c (HbA1c), used in clinical studies as a measure of
glycemic control, may not always accurately reflect the biolog-
ical effect of hyperglycemia because transient spikes in glucose
do not result in overall changes in HbA1c and/or because HbA1c
levels can be influenced by genetic components unrelated to
glucose (Soranzo et al., 2010). Third, CAD often occurs beforefrank type 2 diabetes has developed in subjects with insulin
resistance. Fourth, CAD develops over decades, whereas clin-
ical intervention studies to lower blood glucose are usually con-
ducted over a much shorter time span, with the exception of the
positive studies cited above.
The use of animal models to study the effects of diabetes
on atherosclerosis is often complicated by the coexistence of
hyperlipidemia, which overrides the effects of diabetes on
atherosclerosis (Reaven et al., 1997; Renard et al., 2004; Kanter
et al., 2007). In somemodels, however, diabetes increases blood
glucose levels without associated increases in plasma lipids, and
in these models a proatherogenic effect of diabetes can be
observed (Kunjathoor et al., 1996; Gerrity et al., 2001; Renard
et al., 2004; Vikramadithyan et al., 2005). The most commonly
used models are ones in which Ldlr/ or Apoe/ mice are in-
jected with streptozotocin, a toxin that primarily targets beta-
cells. Another model relies on transgenic expression of the
lymphocytic choriomeningitis virus (LCMV) glycoprotein gene
under control of the rat insulin promoter in Ldlr/ mice (Renard
et al., 2004), where diabetes can be induced at will by a single
injection of LCMV, which results in T cell-mediated beta-cell
destruction. Studies using either model have shown that dia-
betes accelerates formation of early, macrophage-rich athero-
sclerotic lesions at susceptible sites in the arterial wall (Renard
et al., 2004; Vikramadithyan et al., 2005) and that this effect
can be prevented by insulin treatment (Renard et al., 2004;
Schuyler et al., 2011; Johansson et al., 2008). In the LCMV
model, diabetes-induced increases in plasma LDL and VLDL
were found to be necessary for progression to lesions that
exhibit intraplaque hemorrhage and a rupture-prone phenotype
(Johansson et al., 2008). These combined data suggest that
hyperglycemia in the setting of a nondiabetes-mediated hyper-
cholesterolemic background is sufficient to promote early lesion
formation (Figure 3), but that accelerated progression of
advanced plaques in diabetic mice, beyond that normally
observed in nondiabetic mice, requires diabetes-induced eleva-
tion of atherogenic lipoproteins.
Endothelial Cells
While there are many in vitro studies that have examined the
direct effect of high glucose on ECs, there is paucity of in vivo
studies. However, there is circumstantial evidence from in vivo
studies both in animals and humans that the endothelium is
particularly sensitive to changes in glucose concentrations.
Investigators have evaluated the effects of acute (%12 hr)
glucose administration on leukocyte adhesion to microvascular
ECs in rodents using intravital microscopy and found evidence
of increased leukocyte rolling and adhesion to microvessels in
the absence (Booth et al., 2002) or presence of coadministered
IL-1b or TNF-a (Azcutia et al., 2010a). The effects of elevated
glucose in these studies were most likely mediated by increased
expression of the adhesion molecules P-selectin, VCAM-1, and
ICAM-1, through pathways mediated by protein kinase C
(PKC) and increased oxidative stress and/or activation of the
NF-kB pathway (Booth et al., 2002; Azcutia et al., 2010b).
Thus, at least acutely, hyperglycemia promotes leukocyte adhe-
sion to endothelial cells, an initial step in atherogenesis, likely
through direct effects of glucose on ECs. Consistently, transient
hyperglycemia induces long-lasting epigenetic changes in the
promoter of the NF-kB subunit p65 in ECs in vitro and in vivo,Cell Metabolism 14, November 2, 2011 ª2011 Elsevier Inc. 579
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Figure 3. Possible Mechanisms through which
Hyperglycemia in ECs, VSMCs, and Macrophages
Promotes Atherogenesis
Hyperglycemia may accelerate formation of early/mid-
stage lesions of atherosclerosis by promoting adhesion
molecule expression in ECs through epigenetic changes,
increased flux through the AR pathway, and maybe
through activation of PKC, RAGE, and increased reactive
oxygen species (ROS) levels. Increased adhesion mole-
cule expression leads to increased monocyte/macro-
phage accumulation and atherogenesis. In VSMCs, a
principal effect of increased glucose uptake appears to be
increased secretion of the chemokineMCP-1, which could
act in concert with the EC changes to bring more mono-
cytes into the growing lesion. Diabetes/hyperglycemia
also promotes an inflammatory phenotype in macro-
phages, which most likely further contributes to early
atherogenesis. The effects of hyperglycemia on both ECs
and macrophages are most pronounced in the presence
of an inflammatory environment. Lps, lipoproteins.
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Osta et al., 2008). Such epigenetic changes in the NF-kB
pathway appear to be mediated by increased oxidative stress
(Giacco and Brownlee, 2010) and could explain the synergistic
effects of hyperglycemia and cytokines, but whether these
processes in ECs promote atherosclerosis is not yet known.
Elevated glucose can increase flux through the aldose reduc-
tase (AR)/polyol pathway, in which intracellular glucose is
converted to sorbitol by AR and then further to fructose and
downstream metabolites (Vikramadithyan et al., 2005). Trans-
genic expression of AR in streptozotocin-diabetic Ldlr/ mice
selectively increased the effect of diabetes on atherosclerosis,
whereas overexpression of AR in nondiabetic atherosclerotic
mice had no effect (Vikramadithyan et al., 2005). Recent data
suggest that the proatherosclerotic effect of AR overexpression
is due, at least in part, to endothelial changes (Vedantham et al.,
2011). Surprisingly, systemic inhibition of the low endogenous
levels of murine AR selectively increased atherosclerosis in
both nondiabetic and hyperlipidemic diabetic Apoe/ mice
(Srivastava et al., 2009). These data suggest that the effect of
AR on atherosclerosis may depend critically on the expression
level of AR, the absence or presence of hyperglycemia, and/or
effects of specific cell types, but further mechanistic work is
needed to clarify these issues. Clinical trials of AR inhibitors
have so far yieldedmostly unimpressive results onmicrovascular
complications of diabetes, but large human trials using new
classes of AR inhibitors with fewer off-target effects will be
needed to assess the role of AR in the development of cardiovas-
cular disease in humans with diabetes.
Hyperglycemia has also been proposed to exert vascular
effects through de novo synthesis of diacylglycerol and subse-
quent activation of PKC in ECs (Geraldes and King, 2010).
Although more work is needed in this area, PKCb deficiency in
Apoe/ mice leads to diminished atherosclerosis, and this580 Cell Metabolism 14, November 2, 2011 ª2011 Elsevier Inc.protective effect was attributed to the absence
of PKCb in ECs (Harja et al., 2009). Clinical trials
of a PKCb inhibitor (ruboxistaurin) have
so far produced promising or mixed results on
microvascular complications of diabetes (Ger-
aldes and King, 2010).In addition to direct effects of glucose, hyperglycemia-
induced advanced glycation end products (AGEs) have been
proposed as proatherogenic mediators in diabetes. AGEs are
formed by the nonenzymatic reaction of glucose and other gly-
cating compounds with proteins and lipids and can occur both
extracellularly and intracellularly (Giacco and Brownlee, 2010).
AGEs are produced as a result of diabetes, aging, oxidative
stress, or hypoxia, or they can be provided by the diet, and so
they are not specific to diabetes (Yan et al., 2010). Modification
of both intracellular and extracellular molecules by AGEs can
result in altered function of these molecules. For example,
AGE-modified proteins and lipoproteins can bind to and activate
receptors, such as the receptor for AGEs (RAGE). RAGE is ex-
pressed in ECs, where it promotes VCAM-1 expression (Harja
et al., 2008). Indeed, blocking of RAGE function results in protec-
tion against atherosclerosis in hyperlipidemic diabetic mice, but
it also has antiatherogenic effects in nondiabetic mice (Park
et al., 1998; Soro-Paavonen et al., 2008; Harja et al., 2008).
The deleterious effects of RAGE on early atherosclerosis have
been ascribed to changes in ECs. However, a recent study
demonstrates that lack of RAGE in bone marrow-derived cells,
presumably monocyte-derivedmacrophages, results in reduced
necrotic core formation in advanced lesions (Morris-Rosenfeld
et al., 2011). Interestingly, diabetes and RAGE activation regu-
late mostly different sets of genes in the aorta of Apoe/ mice
before the onset of frank atherosclerosis (Bu et al., 2010). These
findings are most likely explained by the ability of RAGE to bind
several different ligands, such as S100/calgranulins and high-
mobility group box 1, which are elevated in a large number of
inflammatory diseases, including diabetes (Yan et al., 2010;
Soro-Paavonen et al., 2008). The relative importance of AGEs
as RAGE activators in diabetes is therefore still unknown, in
part due to the difficulty of specifically blocking AGE-RAGE inter-
actions without blocking RAGE binding to its other ligands in vivo
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relevant AGE preparations (Valencia et al., 2004). Thus, while
endothelial or possibly macrophage RAGE activation may
conspire with diabetes to promote early/mid-stage atheroscle-
rosis, it is as yet uncertain whether RAGE activation is an impor-
tant mediator of hyperglycemia-induced atherosclerosis per se.
Vascular Smooth Muscle Cells
VSMCs take up glucose largely through glucose transporter 1
(GLUT1; SLC2A1). Although elevated glucose concentrations
result in acute downregulation of GLUT1 in cultured VSMCs
(Kaiser et al., 1993), more prolonged exposure to high glucose
does not cause reduced GLUT1 protein levels and hence in-
creases glucose metabolism in VSMCs (Suzuki et al., 2001).
Most of the work assessing the effect of hyperglycemia on
VSMCs has focused on cell proliferation and response to injury,
not atherosclerosis, although hyperglycemia may induce
a proinflammatory phenotype in VSMCs, which could be rele-
vant to atherosclerosis. As an example, a recent study explored
the effect of overexpression of GLUT1 in sm22a-positive
smooth muscle cells in mice, resulting in increased glucose
uptake in these cells (Adhikari et al., 2011). The mice exhibited
increased accumulation of neutrophils in the arterial wall after
vascular injury, suggesting that increased glucose uptake
enhances the proinflammatory phenotype of post-injury
VSMCs. These mice also exhibited increased circulating levels
of MCP-1, haptoglobin, and reduced glutathione (GSH) after
vascular injury, the latter two hypothesized to reflect an
increased glucose flux trough the pentose-phosphate pathway.
Seven days after injury, neointimal VSMCs in the experimental
group showed an increased proliferative index, measured by
Ki67 immunoreactivity, but there was no difference in neointimal
thickness at later time-points. However, as alluded to above,
this was not a hyperlipidemic atherosclerosis model, and so
features of atherosclerosis, such as macrophage accumulation,
were absent.
Macrophages
Whenmacrophages are exposed to high glucose concentrations
in vitro, inflammation is either induced or more often enhanced
in the setting of classical inflammatory stimuli such as lipopoly-
saccharide (LPS). These findings are consistent with studies
demonstrating an increased inflammatory phenotype of macro-
phages from diabetic mice and human subjects (Wen et al.,
2006; Bradshaw et al., 2009; Devaraj et al., 2011). A recent study
examined the effect of diabetes on lesion regression (Parathath
et al., 2011). Atherosclerosis was first induced in Ldlr/ mice
by feeding a Western diet, followed by control or streptozotocin
treatment and then induction of rapid and marked lowering of
plasma cholesterol to promote regression. Both groups showed
a similar reduction in plasma cholesterol, but lesion regression
was hindered in the diabetes group, as evidenced by a less
effective reduction in lesional cholesterol and macrophages.
Macrophages in the diabetic lesions exhibited increased oxida-
tive stress and inflammatory gene expression and a reduced
polarization toward an anti-inflammatory phenotype (Parathath
et al., 2011). Whether diabetes acts mainly by retarding the
egress of macrophages from plaques or by enhancing recruit-
ment of monocytes into these regressing lesions, e.g., by pro-
moting adhesion molecule expression on ECs, is an important
area of future research.Therapeutic Implications
The work presented in this review raises the possibility that
mechanism-based therapy that targets arterial wall cells may
have a special niche in the treatment and prevention of CAD in
subjects with type 2 diabetes. Throughout this review, certain
common pathophysiologic themes have emerged, including
the importance of inflammation, ER stress, and oxidative stress,
particularly in the critical process of advanced plaque progres-
sion. With regard to inflammation, liver X receptors (LXRs)
dampen the inflammatory response in macrophages and other
cells, and oral LXR agonists suppress atherogenesis and plaque
progression in mouse models of atherosclerosis, including
those that have some degree of obesity and insulin resistance
(Bensinger and Tontonoz, 2008). LXR agonists also promote
HDL- and apolipoprotein A-I (ApoA-I)-induced cholesterol efflux
from macrophages by inducing ABCG1 and ABCA1 transporter
proteins, respectively (Bensinger and Tontonoz, 2008). In this
regard, a clinical study with subjects with type 2 diabetes
showed that their monocytes had deceased ABCG1 and choles-
terol efflux potential, both of which were correctable in vitro by
treatment with an LXR agonist (Mauldin et al., 2008). Moreover,
the beneficial effect of the insulin-sensitizing drug pioglitazone,
a thiazolidinedione activator of the transcription factor PPAR-g
and an LXR inducer (Bensinger and Tontonoz, 2008; Ogata
et al., 2009), on carotid atherosclerosis in type 2 diabetes was
highly correlated with its ability to raise HDL (Davidson et al.,
2008). However, systemically administered LXR agonists pro-
mote steatosis, and currently available thiazolidinediones have
been associated with heart failure and possibly bladder cancer
(Bensinger and Tontonoz, 2008). In addition, a statistically sig-
nificant beneficial effect of PPAR-g agonists on CAD in the
PROactive study was shown only for the secondary composite
endpoint of mortality, MI, and stroke, whereas benefit was not
seen in the prespecified primary composite endpoint, which
also included acute coronary syndrome and peripheral vascular
disease (Dormandy et al., 2005).
Another approach to reduce inflammation is by blocking cyto-
kine action. A clinical trial is currently under way to evaluate the
effect of an IL-1b neutralizing antibody on cardiovascular events
(Libby et al., 2011). Such a strategymight be especially beneficial
in diabetes, because IL-1b neutralization might also improve
pancreatic islet function. Finally, as summarized in the section
on hyperglycemia and endothelial cells, preclinical data raise
the possibility that a therapeutic strategy that blocks RAGE-
induced inflammation may have cardiovascular benefit (Park
et al., 1998; Soro-Paavonen et al., 2008; Harja et al., 2008).
Insulin resistance and hyperglycemia have been shown to
activate proatherogenic ER stress pathways in macrophages
and ECs (Tabas, 2010b; McAlpine et al., 2010), and hepatic ER
stress likely contributes to hepatic insulin resistance and thus
atherogenic diabetic dyslipidemia (Ozcan et al., 2004). When
4-phenyl butyric acid (PBA), an ER stress-relieving ‘‘chemical
chaperone,’’ was given to Western diet-fed Apoe/ mice,
vascular ER stress and atherosclerosis were suppressed (Erbay
et al., 2009). Fat-fed Apoe/ mice have a modest level of
obesity and insulin resistance, and the mechanism of protection
by PBA appears to be particularly relevant to saturated fatty
acid-induced ER stress. Although PBA has other effects on cells,
the overall concept that ER stress-relieving therapy may beCell Metabolism 14, November 2, 2011 ª2011 Elsevier Inc. 581
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results of causation studies using genetically targeted mice (Ta-
bas et al., 2010).
The adverse effects of insulin resistance and possibly hyper-
glycemia on oxidative stress in lesional cells raises the possibility
that antioxidant treatment may be useful in this setting. Although
clinical trials using vitamin E have been largely disappointing
(Williams and Fisher, 2005), vitamin E treatment was associated
with a decreased incidence of MI, stroke, and cardiovascular
death in a type 2 diabetes subgroup with a common loss-of-
function polymorphism in the antioxidant protein haptoglobin
(Milman et al., 2008). It is therefore possible that further elucida-
tion of the specific oxidative mechanisms promoted by insulin
resistance and hyperglycemia in specific lesional cell types will
lead to useful antiatherosclerosis therapy in diabetes. For
example, the apparent atherogenic roles of NADPH oxidase in
insulin-resistant VSMCS (Tong et al., 2010) and in advanced le-
sional macrophage death and plaque necrosis (Moore and Ta-
bas, 2011) raise the possibility that drugs that target this oxidase
may have promise. Another study found that deletion of the
antioxidant enzyme glutathione peroxidase-1 promotes athero-
sclerosis in diabetic Apoe/ mice but not in nondiabetic
controls (Lewis et al., 2007), raising the possibility that thera-
peutic enhancement of this enzyme may have benefit in type 2
diabetes.
The above examples represent a few of the many opportuni-
ties in this area, and new ones will continue to emerge based
on human genetic studies examining CAD risk in type 2 diabetes.
For example, a genetic variant in the gene encoding ectonucleo-
tide pyrophosphatase phosphodiesterase 1 (ENPP1), which
inhibits IR signaling, is an independent risk factor for CAD with
particular potency in obese subjects with type 2 diabetes (Bacci
et al., 2011). Moreover, while this review has focused on ECs,
VSMCs, and macrophages, insulin resistance and hypergly-
cemia undoubtedly affect other cell types that affect atheroscle-
rosis. As a prime example, thrombosis is the final arbiter of acute
vascular events, and platelet function, which is abnormal in dia-
betic patients, provides a promising target for drug therapy
(Morel et al., 2010).
Finally, two substantial barriers must be overcome in any
discussion of strategies that target arterial wall cells. First, one
must be able to look beyond orally delivered systemic drugs.
Fortunately, new advances in lesion-targeted therapy, such as
through the use of nanoparticles (Chan et al., 2010), provide
promise in this area. Second, the current use of CAD endpoints
to evaluate drugs that directly affect atherosclerosis is extremely
expensive and time-consuming, and so progress in this area
must be linked to ongoing efforts to develop, validate, and even-
tually use lesional imaging and biomarkers as intermediate
endpoints to identify the most promising drug candidates (Fry-
burg and Vassileva, 2011). In the end, however, cardiovascular
endpoints with a large number of subjects followed for a suffi-
cient period of time must be used to evaluate new therapies.
Concluding Remarks
We have reviewed how insulin resistance and hyperglycemia
may promote atherosclerosis at the level of the arterial wall,
with special emphasis on in vivo studies when available. These
studies have provided evidence that insulin resistance in macro-582 Cell Metabolism 14, November 2, 2011 ª2011 Elsevier Inc.phages and endothelial cells may play important roles in both
atherogenesis and clinically relevant advanced plaque progres-
sion. Hyperglycemia, on the other hand, appears to primarily
promote early stages of lesion formation, although it is possible
that hyperglycemia acts synergistically with other CAD risk
factors and even insulin resistance itself in advanced lesions.
Moreover, the hyperglycemia studies have to be viewed in the
context of currently available clinical data, which have not yet
proven definitively the impact of hyperglycemia on CAD. One
possibility is that hyperglycemia-induced early atherogenesis
leads to an increased probability of CAD later in life. This possi-
bility, perhaps mediated through epigenetic changes, might
help explain the finding that improved glycemic control appears
most effective when implemented earlier in life or soon after dia-
betes diagnosis compared with implementation in patients with
advanced type 2 diabetes and pre-existing cardiovascular
disease or risk factors (Brown et al., 2010; Gerstein et al.,
2011). The prediction that the obesity epidemic will continue to
accelerate the incidence of type 2 diabetes and its deadly con-
sequence of atherosclerotic vascular disease over the next
decades emphasizes the importance of further mechanistic
and translational work in this critical area of biomedical research.
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